Home > Gastroenterology > ECCO 2018 > IBD disease patterns and genetics > Central role of IL-23 in molecular resistance to anti-TNF therapy

Central role of IL-23 in molecular resistance to anti-TNF therapy

Conference
ECCO 2018

Although anti-TNF antibodies have been shown to be effective in many CD patients, a relevant subgroup does not respond to this therapy [14]. The underlying molecular mechanisms associated with endoscopic resistance to anti-TNF therapy were determined by Schmitt et al. [15].

In this study, mucosal and blood cells from 197 CD patients were isolated prior to and during anti-TNF therapy. CD patients responding to anti-TNF therapy displayed a significantly higher expression of TNF receptor 2 (TNFR2) on mucosal T cells than non-responders prior to initiation. However, the expression of IL-23 receptor (IL23R) was not increased. Array analyses of differentiated gene regulation profiles in intestinal biopsies were compared in endoscopic non-responding CD patients and responders during ongoing anti-TNF therapy.

Within the cohort of CD susceptibility genes, there was a significant upregulation of genes that are associated with IL23R-dependent signalling path...



Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on